Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2022 1
2023 8
2024 10
2025 11
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean zaee gepant nasal migraine (34 results)?
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ. Lipton RB, et al. Lancet Neurol. 2023 Mar;22(3):209-217. doi: 10.1016/S1474-4422(22)00517-8. Lancet Neurol. 2023. PMID: 36804093 Clinical Trial.
Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single migraine attack of moderate or severe pain intensity. ...No signal of hepatotoxicity due to zavegepant was identified. INTERPRETATIO …
Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single mig …
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB. Croop R, et al. Headache. 2022 Oct;62(9):1153-1163. doi: 10.1111/head.14389. Epub 2022 Oct 14. Headache. 2022. PMID: 36239038 Free PMC article. Clinical Trial.
Zavegepant, a high-affinity, selective, and structurally unique calcitonin gene-related peptide-receptor antagonist in late-stage development, is formulated as a nasal spray for the acute treatment of migraine. ...There was no signal of hepatotoxicity. CONCLU …
Zavegepant, a high-affinity, selective, and structurally unique calcitonin gene-related peptide-receptor antagonist in late-stage dev …
Zavegepant nasal spray for the acute treatment of migraine: A meta analysis.
Waqas M, Ansari FUR, Nazir A, Hussain KSR, Sarfraz Z, Sarfraz A, Sarfraz M, Kc M. Waqas M, et al. Medicine (Baltimore). 2023 Oct 27;102(43):e35632. doi: 10.1097/MD.0000000000035632. Medicine (Baltimore). 2023. PMID: 37904462 Free PMC article.
BACKGROUND: Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of migraine - a prevalent disease leading to disability and economic burden. ...CONCLUSION: This meta-analysis confirms the effectiveness of …
BACKGROUND: Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of m …
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment.
Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z. Pellesi L, et al. Pain Manag. 2025 May;15(5):279-284. doi: 10.1080/17581869.2025.2494494. Epub 2025 Apr 16. Pain Manag. 2025. PMID: 40238598 Free PMC article. Review.
These drugs block a molecule called calcitonin gene-related peptide (CGRP), which plays a big role in migraine attacks. This article looks at three gepants - ubrogepant, rimegepant, and zavegepant - used to treat migraine when it happens. They come as tablets …
These drugs block a molecule called calcitonin gene-related peptide (CGRP), which plays a big role in migraine attacks. This article …
The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature.
Zhu Z, Tang Y, Li L, Ni H, Liu M, Chen Z, Wang Z. Zhu Z, et al. J Headache Pain. 2025 Mar 10;26(1):48. doi: 10.1186/s10194-025-01984-7. J Headache Pain. 2025. PMID: 40065213 Free PMC article.
BACKGROUND: The latest randomized controlled trial (RCT) revealed that zavegepant, a new nasal inhalation calcitonin gene-related peptide (CGRP) receptor antagonist, has a clear efficacy in the acute treatment of migraine. ...However, compared with other oral …
BACKGROUND: The latest randomized controlled trial (RCT) revealed that zavegepant, a new nasal inhalation calcitonin gene-rela …
Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
Mullin K, Croop R, Mosher L, Fullerton T, Madonia J, Lipton RB. Mullin K, et al. Cephalalgia. 2024 Aug;44(8):3331024241259456. doi: 10.1177/03331024241259456. Cephalalgia. 2024. PMID: 39210835 Free article. Clinical Trial.
METHODS: This phase 2/3, one-year open-label safety study of zavegepant 10 mg nasal spray for the acute treatment of migraine enrolled adults aged 18 years with a history of two to eight moderate to severe monthly migraine attacks. Participants used o …
METHODS: This phase 2/3, one-year open-label safety study of zavegepant 10 mg nasal spray for the acute treatment of migrai …
Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study.
Berman G, Mullin K, Smith T, Mosher L, Sweeney S, Fountaine RJ. Berman G, et al. Headache. 2025 Jul-Aug;65(7):1180-1189. doi: 10.1111/head.14954. Epub 2025 May 20. Headache. 2025. PMID: 40391567 Clinical Trial.
OBJECTIVE: To evaluate the safety and tolerability of zavegepant (ZAV) when used as needed for acute treatment of migraine in patients taking concomitant preventive migraine medications (anti-calcitonin gene-related peptide monoclonal antibodies [CGRP mAbs] o …
OBJECTIVE: To evaluate the safety and tolerability of zavegepant (ZAV) when used as needed for acute treatment of migraine in …
Intranasal zavegepant for the acute treatment of migraine.
Greco G, Monteith T. Greco G, et al. Expert Rev Neurother. 2024 Dec;24(12):1131-1140. doi: 10.1080/14737175.2024.2405741. Epub 2024 Sep 23. Expert Rev Neurother. 2024. PMID: 39314003 Review.
The objective is to review the efficacy, safety, and additional results of the most recent trials investigating intranasal zavegepant for the acute treatment of migraine with or without aura. The authors searched PubMed using the keywords 'zavegepant,' 'Zavzp …
The objective is to review the efficacy, safety, and additional results of the most recent trials investigating intranasal zavegepant …
Zavegepant: First Approval.
Dhillon S. Dhillon S. Drugs. 2023 Jun;83(9):825-831. doi: 10.1007/s40265-023-01885-6. Drugs. 2023. PMID: 37227596 Free PMC article. Review.
In March 2023, zavegepant nasal spray (ZAVZPRET ) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. Clinical development of an oral formulation of zavegepant is currently underway. This article s …
In March 2023, zavegepant nasal spray (ZAVZPRET ) received its first approval in the USA for the acute treatment of migrain …
Nasal spray (Zavegepant) for migraines: a mini-review.
Larik MO, Iftekhar MA, Syed BU, Ansari O, Ansari M. Larik MO, et al. Ann Med Surg (Lond). 2023 May 15;85(6):2787-2790. doi: 10.1097/MS9.0000000000000843. eCollection 2023 Jun. Ann Med Surg (Lond). 2023. PMID: 37363553 Free PMC article.
Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute …
Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research …
30 results